Pharming Group (NASDAQ:PHAR – Get Rating) – Oppenheimer cut their Q3 2022 earnings per share estimates for Pharming Group in a report issued on Friday, August 5th. Oppenheimer analyst H. Singh now anticipates that the company will earn $0.00 per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Pharming Group's current full-year earnings is $0.02 per share. Oppenheimer also issued estimates for Pharming Group's FY2023 earnings at $0.01 EPS and FY2026 earnings at $0.05 EPS.
辉瑞集团(纳斯达克：PharGet评级)-奥本海默在8月5日(星期五)发布的一份报告中下调了Pharming Group 2022年第三季度每股收益预期。奥本海默分析师H·辛格现在预计，该公司本季度每股收益将为0.00美元，低于此前预测的0.01美元。对Pharming Group目前全年收益的普遍估计是每股0.02美元。奥本海默还发布了对Pharming Group 2023财年每股收益为0.01美元和2026财年每股收益为0.05美元的预期。
Pharming Group (NASDAQ:PHAR – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported $0.05 EPS for the quarter. The company had revenue of $46.62 million during the quarter, compared to analysts' expectations of $48.00 million.
Pharming Group Stock Up 3.1 %
Institutional Investors Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Cowen Prime Advisors LLC lifted its holdings in Pharming Group (NASDAQ:PHAR – Get Rating) by 134.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,800 shares of the company's stock after acquiring an additional 8,500 shares during the period. Cowen Prime Advisors LLC's holdings in Pharming Group were worth $132,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.
一家机构投资者最近提高了对Pharming Group股票的头寸。Cowen Prime Advisors LLC在提交给美国证券交易委员会的最近一份13F文件中称，该公司在第四季度将其在制药集团(纳斯达克：PharGet Rating)的持股增加了134.9%。该基金持有14,800股该公司股票，在此期间又购买了8,500股。截至最近一个季度末，Cowen Prime Advisors LLC在Pharming Group持有的股份价值13.2万美元。该公司0.03%的股份由机构投资者持有。
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
生物制药公司Pharing Group N.V.开发蛋白质替代疗法和精准药物并将其商业化，用于治疗美国、欧洲和国际上未得到满足的罕见疾病和医疗需求。该公司的主导产品是Ruconest，一种用于治疗急性遗传性血管性水肿的重组人C1酯酶抑制剂。
- Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- What to Expect from the Markets in a Recession
- MarketBeat: Week in Review 8/1 – 8/5
- 免费获取StockNews.com关于Pharming Group的研究报告(Phar)
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharming Group Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pharming Group和相关公司的最新新闻和分析师评级的每日简要摘要。